Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.
Transcript
What CAR T therapies do you see coming down the pipeline and how do they differ from each other?
That's a loaded question; there's a lot. For the currently approved products, we're learning to use them earlier in lines of care. For the diffuse large B-cell lymphoma population, those indications, and second-line therapy should be coming anytime in the next week to the next couple of months.
Then, we are looking at expanding indications to larger disease states. Obviously, we've had a lot of great approvals with the multiple myeloma products. That recent approval was just on February 28, so I think myeloma is good for a little bit.
In terms of CAR T specifically, for immune effector cells, the bispecifics are the next thing that we're really excited about. We're also looking at allogeneic CAR T products, which are off the shelf, which would really significantly decrease the manufacturing time that we are challenged with at this point.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More